Perspective Therapeutics (NYSEAMERICAN:CATX) Receives Outperform Rating from Wedbush

Key Points

• Wedbush reissued an "Outperform" rating with an $11 price target (implying ~122% upside), and the stock carries a consensus Buy rating with an average analyst target of $12.13.
• Recent results show material operating risk: the company reported a quarterly loss of ($0.51) EPS on just $0.04M revenue, with extremely negative margins and an expected FY EPS of around -0.88, highlighting ongoing cash burn and financing dependence.
• Positive clinical catalyst: updated VMT-α-NET data were accepted for an AACR poster, reporting no dose‑limiting toxicities or serious renal issues and encouraging anti‑tumor activity (76% without progression in an analyzed cohort), supporting program momentum.

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report)'s stock had its "outperform" rating reissued by research analysts at Wedbush in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $11.00 price objective on the stock. Wedbush's price target points to a potential upside of 122.22% from the stock's current price.

Other equities research analysts have also issued reports about the stock. Truist Financial set a $12.00 price target on shares of Perspective Therapeutics in a report on Tuesday. UBS Group reissued a "buy" rating and issued a $7.00 price target (down from $18.00) on shares of Perspective Therapeutics in a report on Friday, November 21st. HC Wainwright boosted their price objective on shares of Perspective Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a research report on Friday, January 30th. BTIG Research reaffirmed a "buy" rating and set a $14.00 price objective on shares of Perspective Therapeutics in a research note on Tuesday. Finally, B. Riley Financial dropped their target price on shares of Perspective Therapeutics from $12.00 to $11.00 and set a "buy" rating for the company in a report on Tuesday, November 18th. One research analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company's stock. Based on data from MarketBeat, Perspective Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $12.13.

Perspective Therapeutics Stock Down 5.2%

CATX opened at $4.95 on Wednesday. The stock's 50 day simple moving average is $4.26 and its 200 day simple moving average is $3.42. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.66 and a current ratio of 8.66. Perspective Therapeutics has a 1 year low of $1.60 and a 1 year high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) last announced its quarterly earnings data on Monday, March 16th. The company reported ($0.51) earnings per share for the quarter. The company had revenue of $0.04 million during the quarter. Perspective Therapeutics had a negative net margin of 9,841.86% and a negative return on equity of 40.03%. As a group, sell-side analysts anticipate that Perspective Therapeutics will post -0.88 EPS for the current fiscal year.

Institutional Trading of Perspective Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Patient Square Capital LP purchased a new stake in Perspective Therapeutics in the third quarter worth about $1,198,000. Siligmueller & Norvid Wealth Advisors LLC purchased a new position in shares of Perspective Therapeutics during the third quarter valued at approximately $565,000. SG Americas Securities LLC bought a new stake in shares of Perspective Therapeutics in the 3rd quarter worth approximately $46,000. Los Angeles Capital Management LLC bought a new stake in shares of Perspective Therapeutics in the 2nd quarter worth approximately $61,000. Finally, Avidity Partners Management LP grew its stake in shares of Perspective Therapeutics by 7.2% in the 4th quarter. Avidity Partners Management LP now owns 3,210,733 shares of the company's stock worth $8,830,000 after buying an additional 216,700 shares during the last quarter. Institutional investors own 54.66% of the company's stock.

Trending Headlines about Perspective Therapeutics

Here are the key news stories impacting Perspective Therapeutics this week:

• Positive Sentiment: Updated [212Pb]VMT-α-NET data accepted for a poster at the AACR Annual Meeting (presentation scheduled April 20). Prior interim data showed no dose‑limiting toxicities, no serious renal issues, and encouraging anti‑tumor activity (76% without progression in an analyzed cohort), which supports the program’s clinical momentum and visibility in oncology. AACR Data Acceptance
• Positive Sentiment: BTIG Research reaffirmed a “Buy” rating and set a $14 price target, signaling continued analyst conviction and providing upside vs. current levels. BTIG Reaffirmation
• Neutral Sentiment: Perspective issued a full-year 2025 results and business highlights update describing progress across its neuroendocrine, melanoma and solid tumor programs and growth of regional finishing facilities; useful for monitoring program cadence but not a near-term revenue driver. Full Year 2025 Results
• Neutral Sentiment: The company is scheduled to release its quarterly earnings on Wednesday — an event that could trigger near-term volatility as investors parse operational and cash‑flow details. Earnings Release Notice
• Negative Sentiment: Latest quarter: reported a ($0.51) EPS and only $0.04M in revenue, with very negative margins and ROE — highlighting ongoing cash burn and dependence on financing or milestones to fund development. This is the principal near‑term negative catalyst pressuring the stock. Quarterly Results
• Negative Sentiment: RBC cut its price target from $18 to $14 (still an Outperform) — a downward revision that tempers upside expectations despite the maintained positive rating. RBC Target Cut

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.